Formulation And Evaluation Of Colon Target Matrix Tablet Of Mesalamine Using Synthetic And Natural Polymer

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory medication used to manage ulcerative colitis and Crohn's disease. It acts as an antioxidant, trapping free radicals, which can be harmful metabolic by-products. Sulfasalazine is metabolized to sulfapyridine and mesalazine. Cassia fistula, also known as the golden shower tree or Indian laburnum, is a tropical tree native to South Asia and Southeast Asia. Its bright yellow flowers attract pollinators and have been used in traditional medicine for centuries to treat ailments like constipation, skin diseases, and respiratory issues. It contains antioxidant and anti-inflammatory compounds that promote overall health. The study aims to develop a multi-particulate drug delivery system for colonic delivery, offering several advantages over conventional single unit dosage forms. The main advantage is the ability to deliver mesalamine directly to the colon, allowing a higher concentration to reach inflamed areas, leading to improved therapeutic outcomes for patients with inflammatory bowel disease. Synthetic and natural polymers are effective in controlling mesalamine release in the colon, ensuring slow and steady release over an extended period. This formulation also improves patient compliance, reducing dosing frequency and providing a more consistent release profile, leading to better disease management and overall health outcomes. The formulation of colon target matrix tablets of Mesalamine of Optimized Batch (F3) using synthetic and natural polymers offers several key advantages for patients with inflammatory bowel disease, including targeted drug delivery, improved therapeutic outcomes, and enhanced patient compliance. The study's findings suggest that the drug should be subjected to further formulation development.